In a recent publication, the therapeutic effect of checkpoint inhibitor therapy could even be predicted by observing the levels of CD8/CD68/CD163/PD-L1 positive cells in non-small cell lung cancer [46]. The gene discussed is CD163; the disease is non-small cell lung carcinoma.